Wednesday, 29 March 2023

BioLargo 2022 Annual Earnings Results Webcast and Conference Call on Monday, April 3, 2023 - 4:30 PM Eastern Time

Update - April 6, 2023 - you can review the financial slides from Monday's Earnings Results Webcast right here:




















Westminster, CA – March 29, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, will host an investor webcast and conference call on Monday, April 3, 2023, at 1:30 pm Pacific / 4:30 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for fiscal year ending December 31, 2022, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/47877 

Teleconference Domestic: 888-506-0062

Teleconference International973-528-0011

Participant Access Code857043


To listen to a replay of the teleconference:

Teleconference Replay Expiration: Monday, April 17, 2023

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 47877


The webcast replay and accompanying presentation materials will be made available for 90 days on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.  


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. 

No comments:

Post a Comment